Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. Tuesday, 12th August, 2025 have 1. Approved the Unaudited Financial Results of the Company ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Ishita Drugs & Industries approved the unaudited financial results for the quarter ended 30th June 2025 (Q1 FY26), along with a clean limited review report from the statutory auditors (CA Mayank Sancheti) with no qualifications. The Board also approved the re-appointment of Mr. Arvind Vilasrao Sapkal as a Non-executive Independent Director for a second 5-year term, subject to shareholder approval at the upcoming 32nd AGM. Additionally, the Board approved amendments to the 32nd AGM notice and gave a general approval to explore and capitalize on business opportunities in other fields, provided such activities fall within the company's Memorandum of Association.
Routine quarterly compliance filing with no negative flags from auditors; the diversification approval signals the company is open to expanding beyond its core pharmaceutical business, which could be a positive growth signal but lacks specifics for now.